Over the past two decades, surgical techniques have increasingly shifted toward minimally invasive approaches, requiring ...

Stifel downgraded Baxter International to ‘Hold’ from ‘Buy’ and slashed the price target to $25 from $36. The analysts ...

We came across a bullish thesis on Baxter International Inc. on DeepValue Capital’s Substack. In this article, we will ...

Baxter International slashed its 2025 profit forecast and posted disappointing quarterly earnings on Thursday, as lingering ...

Healthcare company Baxter International (NYSE:BAX) met Wall Street’s revenue expectations in Q2 CY2025, with sales up 4.3% ...

Deerfield-based Baxter International is still feeling battered by Hurricane Helene and problems with its Novum infusion pumps ...

Baxter International (NYSE:BAX) stock drops after the company's Q2 results miss consensus and Q3 projection fails to meet ...

A longtime shortage of a type of sterile intravenous saline is now resolved, the Food and Drug Administration announced Friday. According to the FDA, sodium chloride 0.9% injection products ...

Baxter International Inc. (NYSE:BAX), a global medtech leader, today reported results for the second quarter of 2025.

Baxter International Inc. closed 30.72% below its 52-week high of $40.49, which the company achieved on September 17th.

The stock's fall snapped a four-day winning streak.